Navigation Links
Suzanne Gagnon, M.D. Joins Idis As Chief Medical Officer
Date:3/12/2013

PRINCETON, N.J., March 12, 2013 /PRNewswire/ -- Idis announced today the appointment of Suzanne Gagnon , M.D., as Chief Medical Officer.  Dr. Gagnon takes on responsibility for leading global medical affairs and providing strategic medical and regulatory leadership across all business divisions.  She will also oversee global quality assurance and compliance.

"We are delighted to have Suzanne join us at this exciting time in the global expansion of Idis. Successful managed access programs require alignment among all stakeholders, from R&D though commercial teams to the physicians treating patients," noted Natalie Douglas , CEO of Idis.  "Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programs that balance stakeholder requirements and effectively address the needs of patients."

The addition of the CMO role and appointment of Dr. Gagnon further strengthens Idis' offering in the US and enhances the Company's ability to deliver patient-centric programs that address the access challenges faced by patients, physicians and companies around the world. 

Dr. Gagnon has more than twenty years leading the medical, regulatory and safety aspects of pharmaceutical product development and has held senior management positions in both academia and in the pharmaceutical and CRO industries.  Formerly CMO and Executive Vice President at ICON Clinical Research for nearly ten years, Dr. Gagnon brings with her senior level experience in medical, regulatory and clinical research operations, as well as safety and risk management expertise.

Dr. Gagnon will be based at Idis' North American headquarters in Princeton, NJ.

About Idis
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. 

Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product's lifecycle from pre-approval to market exit, and in times of unexpected production shortages.

The company's European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.

For more information about Idis please visit www.idispharma.com.

Contact: Christine Quern
Phone: +1 617 761 6791
Email  Christine.quern@fkhealth.com


'/>"/>
SOURCE Idis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Physician Joins Colorado Center for Reproductive Medicine
2. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
3. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
4. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
5. Natalie Douglas, CEO of Idis, Joins Global Genes
6. RARE Project Board of Directors
7. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
8. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
9. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
10. Kevin Johnson Joins United Allergy Services Board Of Directors
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s ... 15-16 at the Gateway Convention Center in Collinsville. , They expect ...
Breaking Medicine News(10 mins):